Stanozolol

Summary

Stanozolol (CHEMBL2079587) is an approved small-molecule anabolic agent (ATC A14AA02) targeting ESR1 and AR; indicated across 1 condition including myelodysplastic syndrome.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A14AA02
• Targets: 2 (ESR1, AR)
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 328.5 Da · C21H32N2O

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2079587
Name	Stanozolol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	25249
ChEBI	CHEBI:9249
ATC	A14AA02
Molecular formula	C21H32N2O
Molecular weight	328.5
InChIKey	LKAJKIOFIWVMDJ-IYRCEVNGSA-N

SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(CC5=C(C4)NN=C5)C

IUPAC name: (1S,2S,10S,13R,14S,17S,18S)-2,17,18-trimethyl-6,7-diazapentacyclo[11.7.0.02,10.04,8.014,18]icosa-4(8),5-dien-17-ol

ChEBI definition: An organic heteropentacyclic compound resulting from the formal condensation of the 3-keto-aldehyde moiety of oxymetholone with hydrazine. Like oxymetholone, it is a synthetic anabolic steroid. It has both anabolic and androgenic properties, and has been used to treat hereditary angioedema and various vascular disorders. It has also been widely abused by professional athletes.

Pharmacological roles (ChEBI): androgen, anabolic agent.

Also known as: Androstanazol, Androstanazole, Estanozolol, NSC-233046, NSC-43193, Stanozolol, Stanozolol ciii, Stromba, Tevabolin, WIN 14833, WIN-14833, Winstrol

Patent coverage: 3,743 distinct patent families (13,336 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ESR1	Estrogen receptor-α	Agonist	6.95	1.7%	P03372
AR	Androgen receptor	Agonist	7.66		P10275

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Estrogen receptor, Adenosine receptor A3, Cytochrome P450 2D6, Androgen receptor, Cytochrome P450 2C9, Cytochrome P450 2C19.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 9 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P15207	7.82	Ki	15	nM	CHEMBL_ACT_7809784
P15207	7.66	IC50	22	nM	CHEMBL_ACT_7809783
ESR1	7.5	Ki	32	nM	CHEMBL_ACT_7807614
CYP2C19	7.32	IC50	48	nM	CHEMBL_ACT_7807591
ESR1	6.95	IC50	113	nM	CHEMBL_ACT_7807613
CYP2C9	5.95	IC50	1128	nM	CHEMBL_ACT_7807593
ADORA3	5.33	Ki	4705	nM	CHEMBL_ACT_7805522
ADORA3	5.08	IC50	8325	nM	CHEMBL_ACT_7805521
CYP2D6	5.03	IC50	9274	nM	CHEMBL_ACT_7807595

Target pathways

Aggregated over 2 target gene(s): ESR1, AR.

Top Reactome pathways

38 total, by targets touching each:

Pathway	Targets	Genes
Nuclear Receptor transcription pathway	2	AR, ESR1
SUMOylation of intracellular receptors	2	AR, ESR1
Nuclear signaling by ERBB4	1	ESR1
PIP3 activates AKT signaling	1	ESR1
Signal Transduction	1	AR
Signaling by Rho GTPases	1	AR
RHO GTPase Effectors	1	AR
Generic Transcription Pathway	1	AR
Constitutive Signaling by Aberrant PI3K in Cancer	1	ESR1
Cellular responses to stress	1	AR
SUMOylation	1	AR
SUMO E3 ligases SUMOylate target proteins	1	AR
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand	1	AR
Metabolism of proteins	1	AR
RHO GTPases activate PKNs	1	AR
Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3	1	AR
Deubiquitination	1	AR
Ub-specific processing proteases	1	AR
Ovarian tumor domain proteases	1	ESR1
Post-translational protein modification	1	AR
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	1	ESR1
RNA Polymerase II Transcription	1	AR
Gene expression (Transcription)	1	AR
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	1	ESR1
Transcriptional regulation by RUNX2	1	AR
RUNX1 regulates estrogen receptor mediated transcription	1	ESR1
ESR-mediated signaling	1	ESR1
RUNX1 regulates transcription of genes involved in WNT signaling	1	ESR1
Regulation of RUNX2 expression and activity	1	ESR1
RUNX2 regulates osteoblast differentiation	1	AR

Dominant GO biological processes

GO term	Targets
negative regulation of transcription by RNA polymerase II	2
regulation of DNA-templated transcription	2
regulation of transcription by RNA polymerase II	2
signal transduction	2
male gonad development	2
nuclear receptor-mediated steroid hormone signaling pathway	2
estrogen receptor signaling pathway	2
positive regulation of DNA-templated transcription	2
positive regulation of transcription by RNA polymerase II	2
mammary gland alveolus development	2
cellular response to estrogen stimulus	2
transcription by RNA polymerase II	2
regulation of gene expression	2
antral ovarian follicle growth	1
epithelial cell development	1

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
myelodysplastic syndrome	2	MONDO:0018881	EFO:0000198

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05024877	PHASE2/PHASE3	UNKNOWN	Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

261 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
TAFENOQUINE	ChEMBL + PubChem	Phase 4 (approved)	AR, ESR1
ARIPIPRAZOLE	ChEMBL	Phase 4 (approved)	AR, ESR1
BITHIONOL	ChEMBL	Phase 4 (approved)	AR, ESR1
CLOMIPHENE	ChEMBL	Phase 4 (approved)	AR, ESR1
CYCLOFENIL	ChEMBL	Phase 4 (approved)	AR, ESR1
DESOGESTREL	ChEMBL	Phase 4 (approved)	AR, ESR1
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	AR, ESR1
ESTRADIOL	ChEMBL	Phase 4 (approved)	AR, ESR1
ESTRADIOL CYPIONATE	ChEMBL	Phase 4 (approved)	AR, ESR1
ESTRADIOL VALERATE	ChEMBL	Phase 4 (approved)	AR, ESR1
ESTRIOL	ChEMBL	Phase 4 (approved)	AR, ESR1
ESTRONE	ChEMBL	Phase 4 (approved)	AR, ESR1
ETHINYL ESTRADIOL	ChEMBL	Phase 4 (approved)	AR, ESR1
ETHYNODIOL DIACETATE	ChEMBL	Phase 4 (approved)	AR, ESR1
ETONOGESTREL	ChEMBL	Phase 4 (approved)	AR, ESR1
HEXACHLOROPHENE	ChEMBL	Phase 4 (approved)	AR, ESR1
HEXESTROL	ChEMBL	Phase 4 (approved)	AR, ESR1
LEVONORGESTREL	ChEMBL	Phase 4 (approved)	AR, ESR1
MEDROXYPROGESTERONE	ChEMBL	Phase 4 (approved)	AR, ESR1
MIFEPRISTONE	ChEMBL	Phase 4 (approved)	AR, ESR1
NORETHINDRONE	ChEMBL	Phase 4 (approved)	AR, ESR1
NORETHYNODREL	ChEMBL	Phase 4 (approved)	AR, ESR1
SPIRONOLACTONE	ChEMBL	Phase 4 (approved)	AR, ESR1
ULIPRISTAL	ChEMBL	Phase 4 (approved)	AR, ESR1
ASOPRISNIL	ChEMBL	Phase 3	AR, ESR1
ETHISTERONE	ChEMBL	Phase 3	AR, ESR1
GESTODENE	ChEMBL	Phase 3	AR, ESR1
GOSSYPOL	ChEMBL	Phase 3	AR, ESR1
ALLYLESTRENOL	ChEMBL	Phase 2	AR, ESR1
CLOFOCTOL	ChEMBL	Phase 2	AR, ESR1
ROMURTIDE	ChEMBL	Phase 2	AR, ESR1
TUROFEXORATE ISOPROPYL	ChEMBL	Phase 2	AR, ESR1
Echothiophate	PubChem	Approved	AR, ESR1
levocarnitine	PubChem	Approved	AR, ESR1
Perindopril	PubChem	Approved	AR, ESR1
Pimavanserin	PubChem	Approved	AR, ESR1
podofilox	PubChem	Approved	AR, ESR1
Propylene Glycol	PubChem	Approved	AR, ESR1
Pyrazinamide	PubChem	Approved	AR, ESR1
Pyridoxine	PubChem	Approved	AR, ESR1
Quinaprilat	PubChem	Approved	AR, ESR1
Vorapaxar	PubChem	Approved	AR, ESR1
FULVESTRANT	ChEMBL + PubChem	Phase 4 (approved)	ESR1
MEGESTROL	ChEMBL + PubChem	Phase 4 (approved)	AR
ABIRATERONE	ChEMBL	Phase 4 (approved)	AR
ACETOPHENAZINE	ChEMBL	Phase 4 (approved)	ESR1
ALECTINIB	ChEMBL	Phase 4 (approved)	ESR1
APALUTAMIDE	ChEMBL	Phase 4 (approved)	AR
APOMORPHINE	ChEMBL	Phase 4 (approved)	ESR1
ASPIRIN	ChEMBL	Phase 4 (approved)	ESR1
AZTREONAM	ChEMBL	Phase 4 (approved)	ESR1
BAZEDOXIFENE	ChEMBL	Phase 4 (approved)	ESR1
BECLOMETHASONE DIPROPIONATE	ChEMBL	Phase 4 (approved)	AR
BELINOSTAT	ChEMBL	Phase 4 (approved)	ESR1
BENZBROMARONE	ChEMBL	Phase 4 (approved)	ESR1
BETAMETHASONE	ChEMBL	Phase 4 (approved)	AR
BEXAROTENE	ChEMBL	Phase 4 (approved)	ESR1
BICALUTAMIDE	ChEMBL	Phase 4 (approved)	AR
BISACODYL	ChEMBL	Phase 4 (approved)	ESR1
BROMHEXINE	ChEMBL	Phase 4 (approved)	AR